All In Biotech

Drug Trial Radar · NCT05249101

A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat Plus Capecitabine or Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on FOLFIRINOX

Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Aug 15, 2022

Primary completion

Jun 2026

Study completion Jul 2026

Sponsor

Lead sponsor
CG Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Feb 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 1b/2, dose-escalation, randomized, multicenter study to assess the efficacy, safety, tolerability, and PK of ivaltinostat in combination with capecitabine and capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on a first line fluoropyrimidine-based chemotherapy (e.g., FOLFIRINOX). In Phase 1b, 3 dose levels of ivaltinostat will be studied in combination with a fixed dose of capecitabine to determine the RP2D of ivaltinostat. In Phase 2, patients will be randomized in a 1:1 ratio to the combination of ivaltinostat and capecitabine or to capecitabine monotherapy. A fixed dose for capecitabine 1000 mg/m2 orally twice daily will be taken on Days 1 to 14, and the RP2D of ivaltinostat will be administered intravenously once a week for 2 weeks, followed by 1 week of rest. One cycle consists of 21 days. Tumor response during study treatment will be assessed every 6 weeks up to Cycle 10, then every 9 weeks afterwards using RECIST v1.1 criteria.

Conditions

  • Metastatic Pancreatic Adenocarcinoma

Interventions

  • IvaltinostatDrug

    Ivaltinostat (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate) is a novel anticancer therapeutic candidate that inhibits enzymatic activity of histone deacetylase (HDAC).

  • CapecitabineDrug

    Capecitabine is labeled for monotherapy for the treatment of adjuvant Dukes' C colon cancer and metastatic colon cancer at a recommended dose of 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest. This dose schedule was effective and tolerable in the first line setting for patients with pancreatic cancer (Cartwright, 2002).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs) in phase 1Time frame: 15 months
  2. Incidence of treatment emergent AEs in phase 1Time frame: 15 months
  3. Treatment emergent changes in clinical laboratory tests in phase 1Time frame: 15 months
  4. Progression-Free Survival (PFS) in Phase 2Time frame: 15 months

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • Hoag Medical Group

    Newport Beach, California

  • UCSF Medical Center

    San Francisco, California

  • UCLA Hematology/Oncology, Gastrointestinal Oncology

    Santa Monica, California

  • University Cancer and Blood Center

    Athens, Georgia

  • Community Health Network

    Indianapolis, Indiana

  • Norton Cancer Institute Audubon

    Louisville, Kentucky

  • University Medical Center New Orleans

    New Orleans, Louisiana

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Clinical Research Alliance

    Westbury, New York

  • Penn State Hershey Cancer Institute

    Hershey, Pennsylvania

  • The University of Texas Southwestern Medical Center

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Virginia Cancer Specialists

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.